home / stock / vxrt / vxrt news

VXRT News and Press, Vaxart Inc.

Stock Information
Company Name: Vaxart Inc.
Stock Symbol: VXRT
Market: NASDAQ
Website: vaxart.com
Menu
VXRT VXRT Quote VXRT Short VXRT News VXRT Articles VXRT Message Board
Get VXRT Alerts

News, Short Squeeze, Breakout and More Instantly...
VXRT - Vaxart anticipates funds to extend its cash runway into 2026

2024-06-18 09:54:18 ET More on Vaxart Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript Biggest stock movers today: ADBE, MSM, RH, and more Vaxart to raise $40M via stock offering Seeking Alpha’s Quant Rating on Vaxart Historical earnings da...
VXRT - Vaxart Provides Business Update

— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...

VXRT - US Companies Moving the Markets, Morning edition
Fri, Jun 14, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...

VXRT - Biggest stock movers today: ADBE, RH, and more

2024-06-14 05:05:33 ET More on related stocks: RH (RH) Q1 2024 Earnings Call Transcript Adobe Inc. (ADBE) Q2 2024 Earnings Call Transcript Adobe in charts: Revenue growth continues for both digital media and digital experience segments Vaxart to raise $40M vi...
VXRT - Vaxart jumps 60% on $40M financing

2024-06-14 02:40:35 ET More on Vaxart Vaxart soars after hours on $453M award to evaluate COVID-19 oral pill vaccine candidate Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2 Seeking Alpha’s Quant Rating on Vaxart His...

VXRT - Vaxart Announces $40 Million Underwritten Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...

VXRT - Vaxart soars after hours on $453M award to evaluate COVID-19 oral pill vaccine candidate

2024-06-13 17:16:41 ET More on Vaxart Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2 Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M Seeking Alpha&#x...
VXRT - Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif., June...

VXRT - COVID-19 vaccine makers rebound amid post-pandemic prospects

2024-05-22 14:00:26 ET More on BioNTech, Moderna, etc. Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs Aggressive Strides Forward For Moderna's Cancer Vaccine Pfizer Stock: Rebound Has Started (Technical Analysis) Pfizer launchi...

VXRT - Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

2024-05-13 17:49:08 ET Vaxart, Inc. (VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 p.m. ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer ...
Next 10